文献速递外周动脉疾病

加拿大血管外科医生对外周动脉疾病药物风险降低的认知:2018年更新

Perceptions of Canadian Vascular Surgeons Toward Pharmacologic Risk Reduction in Patients with Peripheral Artery Disease: 2018 Update.
PubMed 文献 · Ann Vasc Surg · 2019-02-13

本研究通过在线问卷评估加拿大血管外科医生在外周动脉疾病(PAD)药物风险降低方面的知识、态度和行为,并与2004年类似调查比较。多数医生认可血管外科医生在PAD管理中的核心作用,但实际处方和行为不足。

要点

  • 仅52%、38%、50%的血管外科医生知晓LDL-C、血压、血糖的推荐目标值。
  • 58%的医生对不足50%的患者常规评估风险因素,不足10%启动或调整降压或ACEI治疗。
  • 与2004年相比,风险因素评估频率和常见心血管药物知识未改善,他汀处方和糖尿病咨询有所改善但仍不理想。

核心结论

  • 加拿大血管外科医生在PAD药物心血管风险降低方面存在显著的知识和行动差距,且自2004年以来改善有限。

主要发现

  • 推荐的低密度脂蛋白胆固醇、血压和血糖目标分别有52%、38%和50%的血管外科医生知晓。
  • 几乎所有参与者认识抗血小板剂量和他汀适应证,但仅29%能识别ACE抑制剂适应证,44%能识别注意事项。
  • 58%的医生对不足50%的患者常规评估风险因素;多数定期提供风险降低咨询,但不足10%启动或调整降压或ACE抑制剂治疗。
  • 与2004年相比,目标值和常见心血管药物知识及风险因素评估频率未变;糖尿病控制咨询和他汀处方率有所改善但仍不理想。
  • 对于有心血管益处的新药,不足10%的医生会在可及时处方PCSK9抑制剂和SGLT2抑制剂。

关键数值与推荐

  • 推荐目标知晓率:LDL-C 52%,血压38%,血糖50%。
  • ACE抑制剂适应证识别率29%,注意事项识别率44%。
  • 58%的医生对不足50%的患者常规评估风险因素;不足10%启动或调整降压或ACE抑制剂治疗。
  • 不足10%的医生会处方PCSK9抑制剂或SGLT2抑制剂(若可及)。

临床怎么用

  • 血管外科医生应常规评估PAD患者的心血管风险因素并启动或调整指南推荐的药物治疗。
  • 需加强血管外科医生对血压、血糖目标值及ACE抑制剂适应证和注意事项的知识教育。
  • 应制定更新的加拿大PAD指南以支持风险降低药物治疗的临床实践。

局限性

  • 为自报告调查,可能高估实际临床行为。
  • 与2004年调查比较为横断面设计,无法确定因果变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vascular surgeons have a central role in managing peripheral artery disease (PAD). This study assessed their knowledge, attitudes, and behaviors regarding pharmacologic risk reduction in PAD and results were compared to a similar 2004 survey conducted by our group. METHODS: An online questionnaire was administered to 161 active members of the Canadian Society for Vascular Surgery. RESULTS: Forty-eight participants (30%) completed the survey. Recommended targets for low-density lipoprotein cholesterol, blood pressure, and glucose were known by 52%, 38%, and 50% of vascular surgeons, respectively. Almost all participants recognized antiplatelet dosages and statin indications, but less than half could identify indications (29%) and precautions (44%) for angiotensin converting enzyme (ACE) inhibitor therapy. A majority (58%) routinely evaluate risk factors in <50% of their patients. Most vascular surgeons regularly provide risk reduction counseling, but less than 10% initiate or modify antihypertensive or ACE inhibitor therapy. Compared to 2004, knowledge of targets and indications/precautions for common cardiovascular medications and frequency of risk factor assessment have not changed. Rates of counseling for diabetes control and statin prescription have improved, but remain suboptimal. Regarding newer medications with cardiovascular benefit, less than 10% would prescribe proprotein convertase subtilisin/kexin type 9 and sodium-glucose cotransporter 2 inhibitors if they were available. The majority of vascular surgeons rate their PAD risk reduction knowledge as average and support an up-to-date Canadian PAD guideline. Most participants believe that risk reduction therapy is best provided by family physicians and internists, but also acknowledge that vascular surgeons should be well-versed in assessing and managing risk factors in PAD. CONCLUSIONS: Significant knowledge and action gaps exist among Canadian vascular surgeons with regards to pharmacologic cardiovascular risk reduction in PAD. Although there is recognition that vascular surgeons are central to the medical management of patients with PAD, few routinely evaluate risk factors and prescribe medications. There is little evidence of sufficient improvement since 2004. New educational and clinical strategies are needed to improve PAD risk reduction pharmacotherapy among Canadian vascular surgeons.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Li B, Salata K, de Mestral C, et al. Perceptions of Canadian Vascular Surgeons Toward Pharmacologic Risk Reduction in Patients with Peripheral Artery Disease: 2018 Update. Ann Vasc Surg. 2019. PMID: 30771465. doi:10.1016/j.avsg.2018.11.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。